Sarcoidosis is one of the most prevalently reported immune system disorders.62 SLE has also been reported as an adverse effect of IFN therapy in HCV-infected patients.63 Cryoglobulinemia is another immune disorder that has been reportedly associated with IFN therapy.64 Type I diabetes mellitus, another autoimmune disorder, has been repeatedly suggested to develop as an adverse effect of IFN therapy.65 Grave’s disease and thyroiditis are other disorders attributed to IFN therapy in HCV-infected patients.66,67. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.